Rituximab therapy of lymphoma is enhanced by orally administered (1 → 3),(1 → 4)-d-β-glucan

Shakeel Modak; Guenther Koehne; Andrew Vickers; Richard J. O’Reilly; Nai-Kong V. Cheung

doi:10.1016/j.leukres.2004.10.008

Rituximab therapy of lymphoma is enhanced by orally administered (1 → 3),(1 → 4)-d-β-glucan

Shakeel Modak, Guenther Koehne, Andrew Vickers, Richard J. O’Reilly, Nai-Kong V. Cheung

Miami Cancer Institute

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Leukemia Research
Volume	29
DOIs	https://doi.org/10.1016/j.leukres.2004.10.008
State	Published - Jun 1 2005

Disciplines

Biology
Oncology
Immunology and Infectious Disease

Access to Document

10.1016/j.leukres.2004.10.008License: Unspecified

Cite this

@article{789fd36bb03d4ee9994b26c7084dd81f,

title = "Rituximab therapy of lymphoma is enhanced by orally administered (1 → 3),(1 → 4)-d-β-glucan",

author = "Shakeel Modak and Guenther Koehne and Andrew Vickers and O{\textquoteright}Reilly, \{Richard J.\} and Cheung, \{Nai-Kong V.\}",

note = "By activating complement, antitumor monoclonal antibodies coat tumor cells with iC3b. β-glucans, naturally occurring glucose polymers, bind to the lectin domain of the leukocyte receptor CR3, prime it for binding to iC3b, and trigger cytotoxicity of iC3b-coated tumor cells.",

year = "2005",

month = jun,

day = "1",

doi = "10.1016/j.leukres.2004.10.008",

language = "American English",

volume = "29",

journal = "Leukemia Research",

}

TY - JOUR

T1 - Rituximab therapy of lymphoma is enhanced by orally administered (1 → 3),(1 → 4)-d-β-glucan

AU - Modak, Shakeel

AU - Koehne, Guenther

AU - Vickers, Andrew

AU - O’Reilly, Richard J.

AU - Cheung, Nai-Kong V.

N1 - By activating complement, antitumor monoclonal antibodies coat tumor cells with iC3b. β-glucans, naturally occurring glucose polymers, bind to the lectin domain of the leukocyte receptor CR3, prime it for binding to iC3b, and trigger cytotoxicity of iC3b-coated tumor cells.

PY - 2005/6/1

Y1 - 2005/6/1

UR - https://www.sciencedirect.com/science/article/pii/S0145212604003807

U2 - 10.1016/j.leukres.2004.10.008

DO - 10.1016/j.leukres.2004.10.008

M3 - Article

VL - 29

JO - Leukemia Research

JF - Leukemia Research

ER -

Rituximab therapy of lymphoma is enhanced by orally administered (1 → 3),(1 → 4)-d-β-glucan

Disciplines

Access to Document

Other files and links

Cite this